retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 trial conducted in the USA Retatrutide (Eli Lilly's triple GLP-1/GIP/Glucagon
Pay in 4 interest-free payments of $5.20 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
























